Marc Robillard, Tagworks Pharmaceuticals CEO

Tag­works lands $65M for its take on No­bel-win­ning click chem­istry in bid to ex­pand ADC, ra­dio­phar­ma po­ten­tial

A Dutch-Amer­i­can biotech is out with $65 mil­lion in Se­ries A fund­ing to get in­to the clin­ic with what it calls an ex­pand­ed scope of the pop­u­lar an­ti­body-drug con­ju­gates class af­ter a decade of leg­work it­er­at­ing on the orig­i­nal click chem­istry find­ings that led to last year’s No­bel Prize.

Tag­works Phar­ma­ceu­ti­cals, found­ed with­in the cor­po­rate labs of Philips Health­care and spun out in 2011, has spent the past 10-plus years work­ing with aca­d­e­mics to get to a point where it can cre­ate so-called click-to-re­lease re­ac­tions. Its ef­forts build on the work out of Joseph Fox’s lab at the Uni­ver­si­ty of Delaware and that of Car­olyn Bertozzi, who is one of three pro­fes­sors to re­ceive the No­bel Prize in Chem­istry last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.